Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)
EICHORPublic-registry site landscape for NCT07743983, “A Study of BGM0504 in Early T2DM With Obesity”, a Type 2 Diabetes (T2DM) study sponsored by BrightGene Bio-Medical Technology Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07743983 (registry record) |
| Study title | A Study of BGM0504 in Early T2DM With Obesity |
| Official title | A Randomized, Open-Label, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety, and Diabetes Remission of BGM0504 Injection Compared With Semaglutide Injection in Early-Stage Chinese Type 2 Diabetes Mellitus Patients With Obesity and Inadequate Glycemic and Weight Control Despite Diet and Exercise Intervention（BRIGHT-1） |
| Sponsor | BrightGene Bio-Medical Technology Co., Ltd. |
| Condition(s) | Type 2 Diabetes (T2DM) |
| Phase | PHASE3 |
| Listed sites | 1 |
| Site countries | China |
At Nanjing Drum Tower Hospital（The Affiliated Hospital of Nanjing University Medical School） — one of the facilities listed on this trial — 2 other studies are actively recruiting Type 2 Diabetes (T2DM) patients at the same facility (public registry, as of August 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Patient-friendly overview of this study: eichor.com/study/NCT07743983.
Eichor generates a preliminary site-risk snapshot for NCT07743983 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →